You are here: Industry Insights > psoriasis

News List

Lilly's Taltz (ixekizumab) Receives the First U.S. FDA Approval for Label Update to Include Data for Psoriasis Involving the Genital Area drugs
May 31, 2018
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label update for Taltz (ixekizumab) injection 80 mg/mL to include data in psoriasis involving the genital area.
US green lights new biologic for psoriasis pharmatimes
March 23, 2018
The US Food and Drug Administration has approved Sun Pharma’s Ilumya as a new treatment option for adults with moderate-to-severe plaque psoriasis.
Sun Pharma Announces U.S. FDA Approval of ILUMYA™ (tildrakizumab-asmn) for the Treatment of Moderate biospace
March 22, 2018
Sun Pharmaceutical Industries Ltd. today announced that FDA has approved ILUMYA™ for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
Next Generation Biologics, Janssen's Tremfya, Eli Lilly's Taltz, and Novartis' Cosentyx, Raising the biospace
March 09, 2018
The past three years have brought with them a flurry of branded biologic approvals in dermatology, including four biologics for psoriasis alone
In a crowded market, AbbVie may still have a best-in-class psoriasis prospect up its sleeve: analyst fiercepharma
December 07, 2017
The last few years have seen a wave of new biologics take the psoriasis market by storm. But a best-in-class product may still be on its way, one analyst says.
Vanilla compound found to prevent psoriasis pharmafile
December 06, 2017
Psoriasis is a big pharmaceutical market, it’s the most common autoimmune disease in the US and as many as 7.5 million citizens have the condition.
Taltz Receives FDA Approval for Active Psoriatic Arthritis americanpharmaceuticalreview
December 06, 2017
Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) has approved Taltz (ixekizumab) injection 80 mg/mL for the treatment of adults with active psoriatic arthritis (PsA).
Janssen launches Tremfya in UK to treat psoriasis pharmaceufical-technology
November 27, 2017
Janssen has announced the availability of Tremfya (guselkumab) in the UK for adults with moderate-to-severe plaque psoriasis.
UK launch for Janssen’s novel psoriasis biologic Tremfya pharmatimes
November 27, 2017
Janssen has announced the launch of Tremfya in the UK for adults with moderate to severe plaque psoriasis, following a green light from European regulators
Psoriasis patients at greater risk of type 2 diabetes, study reveals pharmafile
November 16, 2017
Researchers at the University of Pennsylvania’s Perelman School of Medicine have discovered that people with psoriasis are more at risk of developing type 2 diabetes, with more severe forms of the condition being linked to greater risk.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page